PATENT CLAIM ANALYSIS

Application Number: 15902143
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-10
Patent Classification: ["548", "400000"]

Abstract:
The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

Claim (Index 14):
The method of  claim 13 , further comprising co-administering an additional therapeutic agent.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 88.0
- Lexical Diversity: 1.41667
- Patent Class: 548.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14823057', '13529542', '13262888', '13935016', '13935021']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7463991902974354
- 35 USC 102 Novelty (BERT): 0.5449488439361985
- Combined Prediction Score: 0.7262541556613117
- Mean Citation Score: 389.475964
- Max Citation Score: 396.6954
- Similarity Product: 294.1291232815504

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test